Podcasts about RR

The Derm on RheumNow podcast is a review of recent citations and content curated for dermatologists – addressing Psoriasis, PsA, CLE, calcinosis, CTD skin disorders. dermatology drugs, biologics, and JAK inhibitors. Features Dr. Jack Cush, Editor at RheumNow.com. Show Notes: FDA Grants Priority Review to Zasocitinib for Plaque Psoriasis. Regulatory decision expected 1st quarter 2027. Supported by phase 3 RCTs, 3000 pts -- LATITUDE PsO 3001 and 3002 clinical trials. https://t.co/o7oqxSXHSw Systematic review of 290 psoriasis pregnancies 211 live births (73%) finds biologic exposure (UST 241, 42 TNFi) during PREG assoc w/ favorable maternal/fetal outcomes. Only 24 cont either CZP or ADA throughout PREG. Rates of miscarriage, LBW, congenital anomalies, comparable w/ https://t.co/H5GLrvxwPv SELECT-PsA 2 subanalysis of 195 active PsA not responding to TNFi shows switching to upadacitinib 15 (vs PBO) was superior @wk 24 - ACR20 (58% vs 22%), ACR50 (38% vs 9.5%), ACR70 (22% vs 0%), MDA (24% vs 3%) & maintained thru wk 152. Switching MOAs makes sense! https://t.co/YEkZuQ95Mu Do biologic Rx lower risk of PsA? Metanalysis (15 studies, 124,138 psoriasis pts, 778K PYrs F/U), showed Biologic use assoc w/ lower risk of PsA (HR 0.54); best for IL-17i (0.65) & IL-12/23 or IL-23i (0.46) vs TNFi. IL-23i superior to IL-17i (HR 0.67) https://buff.ly/N4froBW OL study of tofacitinib in 20 juvenile DM pts w/ calcinosis cutis (11 boys; age 10.4 yrs; CC x 31 mos). Calcinosis assessed by CT scan showed decr Agatston score from 6,349 to 4,007. No SAE. https://t.co/UDLLwce3mp Metanalysis of Metabolic syndrome (MetS) in #SLE (65 articles, 11K pts). MetS prevalence 27% (higher in males (36 vs 27%). HCQ assoc w/ signif less MetS (OR 0.66), but more w/ CTX (1.39), AZA (1.25), MMF (1.13), but not steroids or MTX. MetS pts were older, obese, w/ high Chol & LDL https://buff.ly/VQNvSI9 TriNetX retrospective EHR study showed VTE in #RA not incr by taking JAKi. Pts undergoing THA/TKA Rx w/ JAKi (n 284) vs TNFi (n 288). VTE- 17 JAKi (6%) vs 11 TNFi (3.8%)- nonsignif incr (RR 1.57) https://t.co/OM5ipieQtr In 2022, Overweight & obesity affect 65.8% of Swiss PsA pts (vs gen pop.= 43%) and has increased since 2007. Obesity was assoc w/ elevated CRP (56% vs 37%), Inc Pt global assess (3.2 vs 2.8), & MD global (2.5 vs 2.1) & lower EQ-5D-3L(0.7 vs 0.8). https://t.co/xPoy4dgvlD Study of 119 Rheum pts on GLP-1 Rx (65% T2DM, 35% obesity; mean BMI 35). @ 12 mos wt loss −7.7 kg & 56% improved 1 BMI category. Signif decr in A1c, FBS, lipids, LDL, TG, ESR & CRP. GLP-1RAs useful cardiometabolic benefits https://t.co/fdNtvGu8Vb~ Estimated 7 million Americans (~1/3 US GLP1 Rxs) get GLP-1 drugs from online compounding source- but these are not FDA approved. They maybe cheaper, but dosing/quality is suspect. FDA needs to close the 503B loophole to outlaw these copycat Rxs https://buff.ly/xezDWaJ Data presented at 2027 ASMBS meeting showed betw 2020-2024, wt loss surgeries dropped 23%, from 230,000 in 2022 to 177,000 in 2024. Less than 1% of eligible pts are now having weight-loss surgery https://t.co/UnYIIBDdnz Together PsA 52 wk data (n 271): ACR50 plus 10% wt loss - 39.2% w/ Taltz & Zepbound vs 1.7% w/ Taltz alone. Together PsO trial results (n 274): PASI100 plus 10% wt loss - 30.6% w/ Taltz & Zepbound vs 4.4% w/ Taltz alone. https://t.co/27TBZyL8l1 FDA Approves Brepocitinib to Treat Dermatomyositis Necrotizing arteritis is rare w/ IgA Vasculitis (IgAV). Review compared 30 IgAV-NA to 257 adult IgAV & 196 PAN pts. Overall IgAV-NA is a severe IgAV phenotype with life-threatening complications & should prompt vascular imaging and intensified immunosuppression. IgAV-NA had more more GI bleeds, perforation, surgical abdomen, neuropathy, pancreatitis, livedo, more multi-organ involvement and mortality https://t.co/XdPbGX770D

Before her diagnosis, Melinda Nelson was a plant-based health coach, avid organic juicer, triathlete, and yogi. At 32, she was diagnosed with adrenocortical carcinoma, a rare, one-in-a-million cancer with only one FDA-approved treatment. She found motivation and inspiration in the documentary Heal, which she played on repeat as she fell asleep. After surgery to remove a cortisol-secreting, 24-centimeter adrenal tumor, she started treatment but experienced recurrence in her spine, hips, shoulder, lungs, and liver, leading her to pursue multiple treatments and procedures with a dedicated team of specialists. Her tumors have remained stable and inactive since November 2022, and she continues to support her well-being through complementary practices such as acupuncture, hypnotherapy, and sound baths. In 2024, Melinda became a founding member and vice president of Adrenal Cure Collective, a nonprofit dedicated to advancing adrenal cancer research, and she now co-hosts Talk Cancer to Me, a podcast exploring the realities of life with cancer beyond oncology appointments. adrenalcurecollective.org Tiktok and Instagram: @Melindacnelson Talk Cancer to Me Podcast Radical Remission Docuseries Trailer to Heal Documentary _________ To learn more about the 10 Radical Remission Healing Factors, connect with a certified RR coach or join a virtual or in-person workshop visit www.radicalremission.com.   To learn more about Radical Remission health coaching with Liz or Karla, Click Here   Join our mailing list and you'll receive our free eBook, Kickstart Your Healing: 20 Radical Remission Tips, as a special thank you for joining. Subscribe Here   To watch Episode 1 of the Radical Remission Docuseries for free, visit our YouTube channel here. To purchase the full 10-episode Radical Remission Docuseries visit Hay House Online Learning. Follow us on Social Media: Facebook  Instagram YouTube ______ Our Sponsors: Immunocine Cancer Center is focused on advancing personalized cancer immunotherapy by harnessing the power of the immune system. Their work centers on the Immunocine Dendritic Cell Treatment (IDCT) — a first-in-class therapy designed to train the immune system to recognize and respond to a patient's specific cancer. The process begins by collecting information from the patient's tumor and using it to program specialized immune cells called dendritic cells, which help activate targeted immune responses. A key differentiator in Immunocine's approach is something called double loading — cancer information is delivered to the dendritic cell both inside the cell and on its surface, giving the immune system a more complete blueprint of the cancer it needs to recognize and attack. And while this approach is unique to Immunocine and unique to use therapeutically, it is NOT unique to biology - since this is how the immune system was always meant to work! Immunocine treats patients from around the world at its clinic in Cancun, Mexico, combining advanced immune science with personalized care. As always, patients should first explore whether they may be eligible for a clinical trial in the United States. To learn more, visit Immunocine.com. Website Links https://immunocine.com/ Social Media Instagram — https://www.instagram.com/immunocine/ YouTube — https://www.youtube.com/@immunocinecancercenter Linkedin — https://www.linkedin.com/company/immunocine/ Facebook — https://www.facebook.com/Immunocine/ ____________________________ Nestled in the pristine, natural beauty of British Columbia, The Healing Oasis stands as Canada's first-of-its-kind cancer wellness retreat, where hope reignites and the body is empowered to heal. Here, our renowned naturopathic cancer expert, Dr. Sean Ceaser, designs a fully personalized protocol of advanced, non-toxic therapies—including high-dose IVs like mistletoe and vitamin C, cutting-edge hyperthermia, PEMF, oxygen therapy, red light, and more. Savor daily organic, cancer-fighting meals, rest deeply in serene cabins, immerse in restorative activities like forest walks and yoga, drink mineral-rich living water, and receive emotional support in a peaceful sanctuary that combines world-class care with profound nature immersion to reduce side effects, boost vitality, and spark radical healing. Your journey to feeling alive again begins today at thehealingoasis.ca. Learn More about The Healing Oasis: Website   Testimonials Video Overview  

Maria Rueff é a Quarta da Manhã, não escapa à polémica dos Globos e ainda recebe das mãos da Joana o Globo de Ouro Mau Humor.

Bola Branca 12h44

Bola Branca 18h14

Noticiário das 5h

Noticiário das 9h

Noticiário das 8h

Noticiário das 7h

Noticiário das 6h

Noticiário das 1h

Noticiário das 3h

Noticiário das 2h

Noticiário das 11h

Duarte Pacheco e Mariana Vieira da Silva debatem o novo regime de arrendamento urbano e abordam as buscas à Polícia Judiciária (PJ) e a acusação do chamado "Caso das Gémeas". No plano europeu, o painel residente junta-se ao eurodeputado João Oliveira para refletir sobre a resposta europeia à escalada do preço dos combustíveis.

Líder da FESAP pede aumentos de 6,5% e reage com veemência à hipótese de o Governo congelar metas da Função Pública à boleia da inflação: "Não me passa pela cabeça". Os sindicatos da Administração Pública reúnem-se com o ministro das Finanças na próxima semana e José Abraão espera a revisão do acordo plurianual de rendimentos face ao aumento do custo de vida e à inflação.

Noticiário das 10h

Noticiário das 4h

Noticiário das 12h

Noticiário das 13h

Noticiário das 14h

Noticiário das 15h

Noticiário das 16h

Noticiário das 17h

Noticiário das 18h

Noticiário das 19h

Noticiário das 20h

Noticiário das 21h

Noticiário das 23h

Noticiário das 22h

Hoje foi o Dia Mundial do Coração e os ouvintes partilharam quais as musicas que lhes partem o coração. Ficámos a saber, também, que algumas musicas românticas não são sobre amor. Recebemos ainda Joana Lemos, uma das primeiras mulheres portuguesas a competir no Rally Dakar.

Bola Branca 12h44

Bola Branca 18h16

En nuestro episodio 531 conversamos con Jonás Gómez, HR Director Cluster CERAN en L'Oréal Colombia sobre: + Evitar tener carreras profesionales aburridas. + RR.HH no debe ser un policía en las empresas. + Ser una empresa basada en las habilidades. + El empleado como dueño de su carrera. + Por qué nos cuesta tanto el cambio. + La seguridad psicológica en el cambio. + Recursos Humanos como arquitecto del futuro. + La IA es una amenaza o aliado. + Data es el motor de la IA. + La transformación personal detrás del cambio. ______________________________________________________________________

Medical Disclaimer: The information shared on This Week in HRV is for educational purposes only and is not intended as medical advice. Always consult a qualified healthcare professional before making changes to your health routine. This week on This Week in Heart Rate Variability, we cover six studies that together sketch the future of HRV science. Each one points in a distinct direction: a new metric for measuring rhythm organization across a large psychiatric population, a systematic content audit of consumer HRV apps, a rigorous benchmark of five noninvasive sensor technologies measured simultaneously in the same subjects, a new mathematical framework that challenges the stationarity assumption underlying conventional HRV analysis, a nonlinear dynamical study of group physiological coordination using attractor reconstruction and neural network clustering, and a deep learning system that extracts HRV from facial video alone to detect driver drowsiness at nearly ninety-five percent accuracy. What unites these studies is not a single topic but a shared direction: the field is expanding its metrics, scrutinizing its tools, rethinking its assumptions, and reaching toward applications that would have seemed impractical not long ago. 1. Heart rate fragmentation in psychiatry: across age stages and association with conventional heart rate variability PUBLICATION: Psychiatry Research: NeuroimagingAUTHORS: XinFan Zhang, AiMei Ye, Min Su, Hao Chai, YanYan Wei, YiYi Yang, YuXuan Xiong, Yin Cui, Dan Zhang, Xiong Jiao, HuiRu Cui, LiHua Xu, XiaoChen Tang, HaiChun Liu, MingLiang Ju, LingYun Zeng, ChunBo Li, LiYing Huang, Jin Gao, JiJun Wang, and TianHong Zhang KEY FINDING: Researchers analyzed resting three-minute electrocardiograms from 3,813 patients with schizophrenia, depressive disorder, anxiety disorder, or sleep disorder, ranging in age from 10 to 80 years, treated at the Shanghai Mental Health Center. The study derived both heart rate fragmentation indices—specifically the percentage of inflection points (PIP) and the related percentage of alternating segments (PAS)—alongside conventional HRV measures including RMSSD, SDNN, low-frequency power, and high-frequency power. Heart rate fragmentation increased systematically across age groups, while every conventional HRV index declined. That divergence is the central finding: aging appears to produce both less variability and less organized variability, and these are not the same thing. Partial Spearman correlations and multivariable linear regression confirmed that PIP retained independent associations with all conventional HRV metrics, even after adjusting for available covariates, with the strongest association observed for high-frequency power. Sex differences in fragmentation were confined to adolescence and early adulthood, with males showing higher PIP than females in those life stages, but these differences disappeared by middle and late adulthood. Diagnostic category had a statistically significant main effect on PIP, but the differences between diagnostic groups were modest and did not meaningfully interact with age. SIGNIFICANCE: Heart rate fragmentation asks a different question than conventional HRV metrics. While RMSSD and SDNN measure how much the intervals between heartbeats vary, fragmentation measures how organized that variability is. The consistent independent relationship between PIP and conventional HRV metrics suggests that fragmentation captures something about rhythm organization that amplitude-based measures do not fully account for. Because fragmentation can be computed from the same R-R interval data used in conventional HRV analysis, there is no additional measurement burden when adding it to existing protocols. Read th...

Noticiário das 16h

Noticiário das 11h

Noticiário das 18h

Noticiário das 19h

Noticiário das 23h

Edição da Noite

Noticiário das 13h

A Joana liga em direto de Paris para falar do seu espetáculo e do Globo de Ouro que ganhou ontem, a Ana e a Inês dão gargalhadas a ler anúncios antigos de motores de carro e assistimos ao trailer de "Rocky VII - batalha da espreguiçadeira"

Bola Branca 18h15

Bola Branca 12h44

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc A recent analysis used matching-adjusted indirect comparisons to evaluate anitocabtagene autoleucel, teclistamab, and talquetamab for relapsed or refractory (R/R) multiple myeloma, drawing on data from the iMMAGINE-1, MajesTEC-1, and MonumenTAL-1 trials. The analysis compared efficacy and safety outcomes across these CAR T-cell and bispecific therapies, including overall response, depth of response, MRD negativity, cytokine release syndrome, ICANS, infections, and non-relapse mortality. To explore the findings, their potential clinical implications, and key limitations of these indirect comparisons, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Krina Patel, MD, MSc As CAR T-cell therapy options expand for relapsed or refractory (R/R) multiple myeloma, comparative data may help clinicians weigh efficacy and safety when selecting treatment. One recent matching-adjusted indirect comparison of anitocabtagene autoleucel and ciltacabtagene autoleucel drew on data from the iMMAGINE-1 and CARTITUDE-1 trials to evaluate response and safety outcomes, including cytokine release syndrome, ICANS, infections, and non-relapse mortality. To learn about the findings, their clinical implications, and important limitations of the analysis, Dr. Charles Turck speaks with Dr. Krina Patel, Professor in the Department of Lymphoma and Myeloma at the University of Texas MD Anderson Cancer Center in Houston. She also presented these data at the 2026 International Myeloma Society Annual Meeting.

Joana Marques hipnotiza Ana Galvão e Inês Lopes Gonçalves.

Ouvimos e não julgamos quem ajuda os filhos com os TPCs, as Três fazem hipnose e o Buraca Radioshow apresenta o Roda da Morte e a terapeuta de casal mais agressiva de sempre.

Joana Marques apresenta-nos Fernandino, um respeitável opinion maker do instagram.